%PDF-1.3
%
4 0 obj
<>>>/BBox[0 0 612 792]/Length 133>>stream
xͱ ᝧ8Bik]\Y܆Ґ?97(&Fjf
$.%=k
jaIOv9.҉0GZsYccZw? M'V;HoqV_V-S?/)t
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 133>>stream
xͱ ᝧ8Bik]\Y܆Ґ?97(&Fjf
$.%=k
jaIOv9.҉0GZsYccZw? M'V;HoqV_V-S?/)t
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 133>>stream
xͱ ᝧ8Bik]\Y܆Ґ?97(&Fjf
$.%=k
jaIOv9.҉0GZsYccZw? M'V;HoqV_V-S?/)t
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 133>>stream
xͱ ᝧ8Bik]\Y܆Ґ?97(&Fjf
$.%=k
jaIOv9.҉0GZsYccZw? M'V;HoqV_V-S?/)t
endstream
endobj
7 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2019-04-22T16:11:40-07:00
2019-04-18T01:07:39+05:30
application/pdf
MAB-2019-0002-ver9-Kato_3P 75..78
uuid:b10354a0-dfe2-4f3d-aa42-3bd7dbc48796
uuid:a5834272-04e6-4289-85d7-e909b74066fc
endstream
endobj
8 0 obj
<>stream
x+ |
endstream
endobj
9 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
10 0 obj
<>stream
x+ |
endstream
endobj
11 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
12 0 obj
<>stream
x+ |
endstream
endobj
13 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
14 0 obj
<>stream
x+ |
endstream
endobj
15 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
17 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(ant)12.7(itu)13.7(mor)-586.2(act)11.5(ivi)13.7(ty)-595.6(of)-595.4(CM)13.1(ab-)12.8(43)-595.4(aga)11.7(ins)14(t)-600.2(m)0(o)13.8(use)-591.8(xen)12.8(ogr)14(aft)]TJ
0 -1.1174 TD
[(mod)12.7(els)-263.6(of)-272.9(hum)12.8(an)-268.3(col)12.7(on)-272.9(ca)12.8(nce)11.7(r.)]TJ
/F5 1 Tf
8.9663 0 0 8.9663 62.022 683.5463 Tm
[(Materials)-332.7(and)-338.2(Methods)]TJ
/F8 1 Tf
0 -1.8336 TD
[(Cell)-336.3(lines)]TJ
/F3 1 Tf
9.843 0 0 9.843 72 650.6644 Tm
[(Caco-2)-453.4(was)-454.4(obtained)-454.9(from)-454.8(the)-448.1(American)-458(Type)-456(Culture)]TJ
-1.0137 -1.1116 TD
[(Collection)-337.4(\(ATCC,)-329.8(Manassas,)-338.6(VA\))-333.3(and)-327(was)-333.4(cultured)-333.9(in)-330.6(the)]TJ
T*
[(Du)20(lb)20.7(ec)12.8(co)19.7(s)-618.3(mo)19.6(di)15(e)19.8(d)-628.9(E)0(a)18.5(g)0(l)15(e)0()19.7(s)-628.7(me)18.4(di)20.7(um)-625.5(\(D)20(ME)18.7(M\))-625.1(me)18.4(di)20.7(um)]TJ
0 -1.1174 TD
[(\(N)20(ac)18.5(al)13.8(ai)-596.7(Te)18.5(sq)21(ue)19.7(,)-608.2(I)0(n)15.1(c)0(.)23.1(,)-608.2(Ky)20(ot)15(o,)-597.8(Ja)19.9(pa)19.7(n\))-595.4(su)15.3(pp)20.8(le)19.6(me)18.4(nt)20.7(ed)-596.6(wi)14.1(th)]TJ
0 -1.1116 TD
[(10)20.8(%)-244.1(h)0(e)19.7(a)0(t)19.5(-)0(i)20.7(n)0(a)19.7(c)0(t)13.8(i)0(v)20.7(a)0(t)19.5(e)0(d)-233.7(f)0(e)19.7(t)0(a)19.6(l)-243.1(bo)20.8(vi)20.7(ne)-233.7(se)19.9(ru)20.9(m)-244.2(\()0(F)21(B)0(S)20(;)0(T)19.5(h)0(e)19.7(r)0(m)13.9(o)-237.2(Fi)20.9(sh)15.3(er)]TJ
T*
[(Sc)19.8(ie)19.5(nt)14.9(i)20.9(c,)-622(In)20.9(c.)17.3(,)-631.2(W)0(a)17.4(l)0(t)20.6(h)0(a)19.7(m)0(,)-622.1(M)0(A)13.3(\))0(,)-620.8(1)0(0)20.8(0)-156.6(U/)19.8(mL)-626.7(of)-618.5(pe)19.7(ni)15(ci)19.5(ll)20.6(in)20.7(,)]TJ
T*
[(10)20.8(0)]TJ
/F9 1 Tf
1.6358 0 TD
(m)Tj
/F3 1 Tf
.5414 0 TD
[(g/)14.9(mL)-246.5(of)-255.6(st)20.9(re)19.7(pt)20.7(om)19.6(yc)13.9(in)20.7(,)-256.9(a)0(n)19.7(d)-266(25)]TJ
/F9 1 Tf
11.9629 0 TD
(m)Tj
/F3 1 Tf
.5414 0 TD
[(g/)20.7(mL)-252.3(of)-249.8(am)18.5(ph)20.8(ot)20.7(er)14(ic)19.5(in)-250(B)]TJ
-14.6815 -1.1174 TD
[(\(N)20(ac)18.5(al)13.8(ai)-395.2(Te)18.5(sq)15.3(ue)19.7(,)-406.6(I)0(n)15.1(c)0(.)23.1(\))-410(at)-400.9(37)]TJ
/F7 1 Tf
11.5828 0 TD
()Tj
/F3 1 Tf
.3859 0 TD
[(C)-411.1(i)0(n)-399.7(a)-411.2(hu)20.8(mi)19.5(di)20.7(e)19.8(d)-410(a)0(t)19.6(m)0(o)19.6(s)0(p)15.3(h)0(e)19.7(r)0(e)]TJ
-11.9687 -1.1116 TD
[(co)19.7(nt)20.7(ai)13.8(ni)20.7(ng)-261.4(5%)-256.7(CO)]TJ
7.3823 0 0 6.5614 134.6456 561.3731 Tm
(2)Tj
9.843 0 0 9.843 140.9952 563.0172 Tm
[(an)13.9(d)-266(9)0(5)20.8(%)-272.9(ai)19.5(r.)]TJ
/F8 1 Tf
8.9663 0 0 8.9663 62.022 534.3873 Tm
(Antibodies)Tj
/F3 1 Tf
9.843 0 0 9.843 72 517.9464 Tm
[(The)-287.9(mouse)-295.7(anti-CD133)-290.8(mAb)-293.4(CMab-43)-293(was)-287.4(developed)-295.8(as)]TJ
-1.0137 -1.1116 TD
[(described)-191.9(elsewhere.)]TJ
7.3823 0 0 6.5614 143.6598 511.3699 Tm
(\(16\))Tj
9.843 0 0 9.843 157.833 507.0046 Tm
[(CMab-43)-195.1(hybridoma)-185.2(was)-195.2(cultured)-189.9(in)]TJ
-9.7339 -1.1174 TD
[(Hybridoma-SFM)-392.6(medium)-390.5(\(Thermo)-391.4(Fisher)-393.4(Scientic,)-391.3(Inc.\),)]TJ
0 -1.1116 TD
[(supplemented)-467.3(with)-460.5(100)-164.6(U/mL)-462.8(of)-457.2(penicillin,)-466.7(100)]TJ
/F9 1 Tf
20.2684 0 TD
(m)Tj
/F3 1 Tf
.5529 0 TD
[(g/mL)-462(of)]TJ
-20.8213 -1.1116 TD
[(streptomycin,)-544.5(and)-545.9(25)]TJ
/F9 1 Tf
9.1867 0 TD
(m)Tj
/F3 1 Tf
.5529 0 TD
[(g/mL)-542.6(of)-543.6(amphotericin)-542.4(B)-543.5(\(Nacalai)]TJ
-9.7397 -1.1174 TD
[(Tesque,)-307.1(Inc.\))-308.4(at)-303(37)]TJ
/F7 1 Tf
7.6546 0 TD
()Tj
/F3 1 Tf
.3917 0 TD
[(C)-307.4(under)-306.1(a)-301.8(humidied)-306.2(5%)-308.5(CO)]TJ
7.3823 0 0 6.5614 259.1432 461.4802 Tm
(2)Tj
9.843 0 0 9.843 265.833 463.1243 Tm
[(and)-304(95%)]TJ
-20.7061 -1.1116 TD
[(air)-534.5(atmosphere.)-537.5(CMab-43)-540.7(was)-535(puried)-532.9(using)-535.3(Protein)-538.8(G-)]TJ
T*
[(Sepharose)-485.3(\(GE)-477.6(Healthcare)-484.5(Bio-Sciences,)-488.8(Pittsburgh,)-481(PA\).)]TJ
0 -1.1174 TD
[(Control)-187.5(mouse)-186.3(IgG)-182.7(was)-189.5(purchased)-186(from)-184.1(Sigma-Aldrich)-191.7(Corp.)]TJ
0 -1.1116 TD
[(\(St.)-283.1(Louis,)-280.8(MO\).)]TJ
/F8 1 Tf
8.9663 0 0 8.9663 62.022 390.6708 Tm
[(Antitumor)-335.1(activity)-332.8(of)-336.7(CMab-43)]TJ
/F3 1 Tf
9.843 0 0 9.843 72 374.2298 Tm
[(Female)-305(BALB/c)-305.8(nude)-299.3(mice)-307.6(\(6-week)-304.6(old\))-304(were)-301.3(purchased)]TJ
-1.0137 -1.1116 TD
[(from)-339.6(Charles)-345(River)-341.9(\(Kanagawa,)-348(Japan\))-342.8(and)-338.5(used)-339.4(in)-342.1(experi-)]TJ
0 -1.1174 TD
[(ments)-462.9(when)-461.5(they)-460.7(were)-468.3(10)-457.2(weeks)-463.5(old.)-461.9(Caco-2)-465(\(0.3)-168(mL)-459.6(of)]TJ
0 -1.1116 TD
(1.33)Tj
/F7 1 Tf
1.918 0 TD
()Tj
/F3 1 Tf
.72 0 TD
(10)Tj
7.3823 0 0 6.5614 97.7952 345.7133 Tm
(8)Tj
9.843 0 0 9.843 101.537 341.348 Tm
[(/mL)-386(in)-394(DMEM\))-389.5(were)-393.5(mixed)-388.2(with)-391.4(0.5)-166.9(mL)-390.5(of)-388.1(BD)]TJ
-4.0145 -1.1116 TD
[(Matrigel)-375.3(Matrix)-371.8(Growth)-371.3(Factor)-371.7(Reduced)-375.1(\(BD)-368(Biosciences,)]TJ
T*
[(San)-488.1(Jose,)-492.4(CA\).)-486.7(A)-491.5(100-)]TJ
/F9 1 Tf
9.9413 0 TD
(m)Tj
/F3 1 Tf
.5529 0 TD
[(L)-486.1(suspension)-489.8(\(containing)-492.9(5)]TJ
/F7 1 Tf
11.7037 0 TD
()Tj
/F3 1 Tf
.72 0 TD
(10)Tj
7.3823 0 0 6.5614 297.4109 323.8298 Tm
(6)Tj
9.843 0 0 9.843 62.022 308.4661 Tm
[(cells\))-216.3(was)-212.5(injected)-214.3(subcutaneously)-214.6(into)-212(the)-211.9(left)-207.4(anks)-213.7(of)-209.5(nude)]TJ
0 -1.1116 TD
[(mice.)-247.7(After)-243.8(day)-240.6(1,)-246.4(50)]TJ
/F9 1 Tf
8.6568 0 TD
(m)Tj
/F3 1 Tf
.5529 0 TD
[(g)-243(o)0(f)-244.1(CMab-43)-246.9(and)-240.6(control)-245.2(mouse)-243.9(IgG)]TJ
-9.2098 -1.1116 TD
[(in)-180.9(100)]TJ
/F9 1 Tf
2.6322 0 TD
(m)Tj
/F3 1 Tf
.5529 0 TD
[(L)-180.8(PBS)-182.6(were)-186.1(injected)-185.5(into)-183.2(the)-183.1(peritoneal)-187.7(cavity)-182(of)-180.7(each)]TJ
-3.1851 -1.1174 TD
[(mouse.)-351(Additional)-359.2(antibodies)-353.4(were)-353.1(then)-351.3(injected)-358.3(on)-347.8(days)-356.7(7)]TJ
0 -1.1116 TD
[(and)-263.7(14.)-259.1(The)-264.8(tumor)-260.3(diameter)-267.2(and)-263.7(volume)-262.6(were)-266.8(determined)-263.6(as)]TJ
T*
[(previously)-294.4(descri)-8.8(bed.)]TJ
7.3823 0 0 6.5614 146.8346 258.066 Tm
(\(23\))Tj
9.843 0 0 9.843 162.085 253.7007 Tm
[(The)-293.6(mice)-296.1(were)-295.6(eutha)-8(nized)-295.9(19)-290.2(days)]TJ
-10.1659 -1.1174 TD
[(after)-388(cell)-387.1(implantation.)-383.7(All)-390.3(data)-381.2(were)-387.7(expressed)-387.4(as)-389.1(mean)]TJ
/F7 1 Tf
23.7415 0 TD
()Tj
/F3 1 Tf
-23.7415 -1.1116 TD
[(SEM.)-371.5(Statistical)-378.9(analysis)-373.9(was)-373.8(performed)-376.2(using)-374.1(the)-373.2(Tukey)]TJ
T*
[(Kramers)-508.3(test.)]TJ
/F10 1 Tf
6.4336 0 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(<)Tj
/F3 1 Tf
.72 0 TD
[(0.05)-502.1(was)-500.5(considered)-509.7(to)-503.4(be)-504.5(statistically)]TJ
-7.8217 -1.1174 TD
(signicant.)Tj
/F5 1 Tf
8.9663 0 0 8.9663 62.022 181.1905 Tm
[(Results)-337.2(and)-331.9(Discussion)]TJ
/F3 1 Tf
9.843 0 0 9.843 72 164.7496 Tm
[(We)-627.7(had)-626.5(previously)-628.5(reported)-627.5(the)-626.6(development)-633.4(of)-624.2(the)]TJ
-1.0137 -1.1116 TD
[(mouse)-416.6(mAb)-414.3(CMab-43)-419.7(against)-413.3(CD133.)]TJ
7.3823 0 0 6.5614 220.3653 158.1732 Tm
(\(16\))Tj
9.843 0 0 9.843 236.7495 153.8078 Tm
[(Flow)-414.2(cytometry)]TJ
-17.7514 -1.1116 TD
[(demonstrated)-576.7(that)-570.3(CMab-43)-575.2(reacted)-571.1(with)-575.7(LN229/CD133)]TJ
T*
[(cells)-301.6(but)-302.9(not)-297.2(with)-299.3(LN229)-301.3(brain)-306.3(tumor)-300.6(cells,)-299.3(which)-301.4(indicates)]TJ
0 -1.1174 TD
[(that)-362.9(CMab-43)-367.9(is)-365(specic)-368.1(for)-360.3(CD133.)-368(CMab-43)-362.1(also)-368.4(recog-)]TJ
0 -1.1116 TD
[(nized)-520.6(as)-515.8(an)-516(endogenous)-520(CD133)-520(in)-514.9(Caco-)-8.8(2)-513.7(colon)-519.4(cancer)]TJ
T*
[(cells.)-714(Western)-714.9(blotting)-712(against)-712.8(LN229,)-707.9(LN229/CD133,)]TJ
0 -1.1174 TD
[(CHO-K1,)-630(CHO/CD133,)-628.7(and)-632.3(Caco-2)-626.2(cells)-629.9(revealed)-629.9(that)]TJ
0 -1.1116 TD
[(CMab-43)-350.6(detected)-359.3(a)-347.8(strong)-352.1(signal)-353.4(at)]TJ
/F9 1 Tf
15.3611 0 TD
(*)Tj
/F3 1 Tf
1.0022 0 TD
[(100)-164.6(kDa)-350.9(in)-353.7(LN229/)]TJ
9.1407 33.4293 TD
[(CD133)-341.5(and)-332.8(CHO/CD133)-343(but)-337.5(detected)-336.3(a)-336.3(moderate)-341.9(signal)-336.1(in)]TJ
0 -1.1116 TD
[(Caco-)-8.8(2)-300.6(cells,)-310.8(which)-301.4(indicates)-313.1(the)-304.1(usefulness)-306.6(of)-307.4(CMab-43)-304.5(in)]TJ
0 -1.1174 TD
[(western)-333.4(blotting.)-329.6(Furthermore,)-330(the)-327.1(calculated)]TJ
/F10 1 Tf
18.7018 0 TD
(K)Tj
/F3 1 Tf
7.3823 0 0 6.5614 503.7164 382.5637 Tm
(D)Tj
9.843 0 0 9.843 512.277 384.2078 Tm
[(values)-325.7(for)]TJ
-20.2396 -1.1116 TD
[(CMab-43)-586.8(against)-580.3(LN229/CD133)-586.4(and)-580.4(Caco-2)-580.1(cells)-583.9(were)]TJ
T*
(4.4)Tj
/F7 1 Tf
1.4169 0 TD
()Tj
/F3 1 Tf
.72 0 TD
(10)Tj
/F7 1 Tf
7.3823 0 0 6.5614 343.9558 366.6897 Tm
(-)Tj
/F3 1 Tf
.5529 0 TD
(9)Tj
9.843 0 0 9.843 355.2377 362.3243 Tm
[(and)-361.6(2.6)]TJ
/F7 1 Tf
3.2254 0 TD
()Tj
/F3 1 Tf
.7142 0 TD
(10)Tj
/F7 1 Tf
7.3823 0 0 6.5614 403.8802 366.6897 Tm
(-)Tj
/F3 1 Tf
.5529 0 TD
(9)Tj
9.843 0 0 9.843 415.1621 362.3243 Tm
[(M,)-356.8(respectivel)-11.2(y,)-355.9(indicating)-359.5(a)-359.4(high)]TJ
-10.3732 -1.1174 TD
[(afnit)-7.8(y)-450.4(for)-452.5(CD133-expressing)-459.3(cell)-456.2(lines.)-453.7(The)-454.9(immunohis-)]TJ
0 -1.1116 TD
[(toche)-8(mical)-608.3(analysis)-615.8(demonstrated)-617(that)-610.6(CMab-43)-609.8(stained)]TJ
T*
[(83.3%)-343(of)-342(colon)-346.6(adenocarcinomas,)-350.6(which)-341.7(indicated)-347.9(the)-344.4(use-)]TJ
T*
[(fulness)-400.2(of)-388.1(CMab-43)-396.7(for)-394.9(immunohistochemical)-398.4(analysis.)]TJ
7.3823 0 0 6.5614 539.8865 322.866 Tm
(\(16\))Tj
9.843 0 0 9.843 313.0582 307.5023 Tm
[(As)-469.4(CMab-43)-465.8(was)-465.9(determined)-465.2(to)-463.1(be)-464.1(an)-464.1(IgG)]TJ
7.3823 0 0 6.5614 495.0424 305.8582 Tm
(2a)Tj
9.843 0 0 9.843 506.6077 307.5023 Tm
[(subclass)-465.7(of)]TJ
-19.6636 -1.1116 TD
[(mouse)-243.9(IgG,)-243.7(it)-238.6(demonstrates)-248.2(the)-240.7(potential)-243.2(of)-244.1(ADCC)-244.4(and)-240.6(CDC)]TJ
T*
(activities.)Tj
7.3823 0 0 6.5614 351.3259 289.9842 Tm
(\(21\))Tj
9.843 0 0 9.843 323.0361 274.6204 Tm
[(To)-210.7(study)-212.8(the)-206.2(antitumor)-214.3(activity)-213.2(of)-209.5(CMab-43)-212.4(on)-203.8(cell)-214.3(growth)]TJ
/F10 1 Tf
-1.0137 -1.1116 TD
[(in)-238.5(vivo)]TJ
/F3 1 Tf
2.7013 0 TD
[(,)-233.8(Caco-2)-246.1(cells)-238.3(were)-238(subcut)-7.7(aneously)-235.7(implanted)-244.3(into)-240.8(the)]TJ
-2.7013 -1.1116 TD
[(anks)-300.1(of)-301.7(nude)-293.6(mice.)-299.5(CMab-43)-304.5(and)-298.2(control)-297.1(mouse)-301.5(IgG)-297.9(were)]TJ
0 -1.1174 TD
[(injected)-214.3(three)-203.8(times)-209.5(\(on)-204.9(days)-207(1,)-206.1(7,)-206.1(and)-206.1(14)-203.8(after)-209.5(cell)-208.6(injections\))]TJ
0 -1.1116 TD
[(into)-471.2(the)-465.4(peritoneal)-475.6(cavity)-470(of)-462.9(mice.)-472.3(Tumor)-468.7(formation)-467.5(was)]TJ
T*
[(observ)-7.5(ed)-504.5(in)-509.2(mice)-514.9(from)-506.7(the)-511.4(control)-510.2(and)-511.3(CMab-43-treated)]TJ
0 -1.1174 TD
[(groups)-357.7(in)-347.9(Caco-2)-355.5(xenograft)-357.9(models.)-352.2(CMab-43)-356.4(signicantly)]TJ
0 -1.1116 TD
[(reduced)-569.9(the)-563.3(tumor)-565.5(development)-570(of)-560.9(Caco-2)-568.6(xenograft)-565.2(in)]TJ
T*
[(comparison)-325.5(with)-322.3(that)-322.6(in)-319.1(control)-320.1(mouse)-318.7(IgG)-320.9(on)-324.7(days)-316.4(12,)-322.4(14,)]TJ
T*
[(and)-234.9(19)-238.3(\(Fig.)-232.4(1\).)-236(Caco-2)-234.6(xenograft)-236.9(mice)-238.5(models)-233.6(on)-232.6(day)-234.8(19)-238.3(are)]TJ
0 -1.1174 TD
[(shown)-357.5(in)-353.7(Figure)-353.3(2A.)-352.1(The)-357(resected)-358.9(tumors)-353.3(of)-353.5(Caco-2)-355.5(xeno-)]TJ
0 -1.1116 TD
[(grafts)-215(are)-212.9(depicted)-208.4(in)-209.7(Figure)-215.1(2B.)-208.3(The)-213(tumor)-208.4(weight)-210.5(of)-209.5(mice)-209.7(in)]TJ
T*
[(CMab-43)-465.8(treated)-460.7(was)-465.9(signicantly)-459.2(lower)-462.7(than)-460.7(that)-460.8(in)-463.1(the)]TJ
0 -1.1174 TD
[(control)-654.2(mouse)-647(IgG)-649.2(group)-644.8(in)-647.4(Caco-2)-649.3(xenograft)-651.6(models)]TJ
0 -1.1116 TD
[(\(Fig.)-347.6(2C\).)-341.8(However,)-343.5(body)-344.2(weight)-343(was)-345(not)-343.3(signicantly)-349.8(dif-)]TJ
T*
[(ferent)-239.4(among)-238.3(the)-240.7(two)-234.7(groups)-236.8(in)-238.5(the)-235(Caco-2)-240.3(xenograft)-236.9(models)]TJ
0 -1.1174 TD
[(\(Fig.)-284.2(2D\).)]TJ
1.0137 -1.1116 TD
.0129 Tc
[(I)-5.4(n)-281.9(con)-5.5(c)-.9(lus)-5.3(i).2(on)-5.5(,)-284.3(C)-.7(Mab-)-5.4(43)-281.9(i)-5.6(s)-281.8(ap)-5.5(plic)-6.6(able)-288.9(for)-287.7(ant)-5.6(i).2(bod)-5.5(y)-281.9(t).1(h)-5.5(e)-.9(r-)]TJ
-1.0137 -1.1116 TD
[(a)-6.5(p).4(y)-673.5(a)-.8(gai)-5.5(n).4(st)-673.6(huma)-6.5(n)-667.7(c)-6.5(o).4(lon)-673.5(can)-5.4(cers)-673.3(e)-.8(x)-5.4(pres)-5.2(s).6(in)-5.4(g)-667.7(C)-6.4(D133)-5.4(.)]TJ
ET
q
1 i
313.625 732.245 m
551.565 732.245 l
551.565 546.123 l
313.625 546.123 l
W n
q
238.023 0 0 186.123 313.625 546.123 cm
/Im1 Do
Q
Q
BT
/F4 1 Tf
9.845 0 0 9.845 313.0582 529.3416 Tm
0 Tc
[(FIG.)-486.5(1.)]TJ
/F3 1 Tf
4.2671 0 TD
[(Antitumor)-483.6(activity)-488.9(of)-485.7(CMab-43)-482.1(against)-487.4(Caco-2)]TJ
-4.2671 -1.0135 TD
[(xenograft)-627.6(model.)-627(Tumor)-623.4(volume)-618.9(of)-623.9(Caco-2)-625.4(xenografts.)]TJ
T*
[(Caco-2)-291.4(cells)-283.9(were)-289.3(injected)-282.6(subcutaneously)-288(into)-286.5(female)-287.2(nude)]TJ
T*
[(mice.)-316.2(The)-316.3(indicated)-318.1(antibodies)-317.8(\(50)]TJ
/F9 1 Tf
14.3388 0 TD
(m)Tj
/F3 1 Tf
.5528 0 TD
[(g/day;)-312.7(2.5)-166.6(mg/kg\))-318.2(were)]TJ
-14.8916 -1.0077 TD
[(administered)-270.3(intraperitoneally)-270.2(on)-261.1(days)-264.1(1,)-263.5(7,)-263.5(and)-263.3(14)-266.9(after)-266.6(cell)]TJ
0 -1.0135 TD
[(inoculation.)-420.4(The)-408.4(tumor)-415.1(volume)-411.5(was)-413.7(measured)-421.3(at)-412.2(the)-413.2(indi-)]TJ
T*
[(cated)-290.8(time)-283.1(points.)-285.9(The)-287.5(values)-290.5(are)-281.7(presented)-288.8(as)-285.2(mean)]TJ
/F7 1 Tf
21.2663 0 TD
()Tj
/F3 1 Tf
.7198 0 TD
(SEM.)Tj
-21.9861 -1.0077 TD
(*)Tj
/F10 1 Tf
.501 0 TD
(p)Tj
/F7 1 Tf
.668 0 TD
(<)Tj
/F3 1 Tf
.7198 0 TD
[(0.01,)-309.2(TukeyKramers)-314(test;)-317.4(SEM,)-307.6(standard)-315.5(error)-311.3(of)-312.9(the)]TJ
-1.8888 -1.0135 TD
(mean.)Tj
/F5 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(76)Tj
48.2754 0 TD
[(KATO)-330.5(ET)-338.7(AL.)]TJ
ET
endstream
endobj
20 0 obj
<>stream
Adobe d C
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz ? NlXմJuD0Ǣca/jΓcy5Šjװ]7.+ī9TS\Wz&~E_Z5jH៙ ;|ywA,֥9Ut
qpX~#@7co 궷:nmWJ@I9 H ?vOC}e0 %wV#3f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lQ[C